1. Introduction

• Definition: Live microorganisms which, when administered in adequate amounts, confer a health benefit on the host.
• Clinical Goal: Establish a healthy commensal microbiome in the preterm gut to prevent dysbiosis, pathological colonization, and systemic inflammation.
• Clinical Scope: Strongest evidence supports use in preterm, Very Low Birth Weight (VLBW) and Extremely Low Birth Weight (ELBW) infants. Evidence for healthy, full-term neonates remains sparse.

2. Mechanisms of Action

Probiotics support gut integrity and immune maturation through several pathways:

• Barrier Enhancement: Strengthens epithelial tight junctions, upregulates tight junction proteins (occludin, ZO-1), and reduces permeability ("leaky gut").
• Competitive Inhibition: Outcompetes pathogens for essential nutrients and mucosal receptor sites.
• Immunomodulation: Upregulates anti-inflammatory cytokines (IL-10) and downregulates pro-inflammatory cytokines (TNF-alpha, IL-6).
• Trophic Mucosal Effects: Upregulates mucin production and ferments carbohydrates into Short-Chain Fatty Acids (SCFAs) to nourish colonocytes.

graph TD
    A[Probiotic Administration] --> B[Barrier Enhancement]
    A --> C[Competitive Inhibition]
    A --> D[Immunomodulation]
    A --> E[Trophic Mucosal Effects]

    B --> B1[Upregulate Tight Junction Proteins] --> B2[Reduce Leaky Gut]
    C --> C1[Block Receptor Sites & Outcompete for Nutrients] --> C2[Inhibit Pathogens]
    D --> D1[Balance Anti- & Pro-inflammatory Cytokines] --> D2[Reduce Inflammation]
    E --> E1[Increase Mucin & SCFA Production] --> E2[Nourish Colonocytes]

3. Clinical Effectiveness (Preterm & ELBW Infants)

Prophylactic probiotics provide established therapeutic benefits in high-risk preterm infants:

• VLBW (<1500g) Infants: Probiotics consistently reduce severe necrotizing enterocolitis (NEC ≥ Stage II), reduce all-cause mortality, and shorten the time to reach full enteral feeds.
• ELBW (<1000g) / Extremely Preterm (<28 weeks) Infants: Benefits for NEC and mortality are observed, though the overall quality of evidence is lower and the effect on late-onset sepsis is less definitive.

Key Clinical Outcomes

4. Strains, Dosage, and Protocol

• Common Strains: Bifidobacterium species (B. infantis, B. lactis, B. bifidum, B. breve) and Lactobacillus species (L. rhamnosus GG, L. acidophilus, L. reuteri). Saccharomyces boulardii (yeast) is generally avoided in patients with central lines due to fungemia risk.
• Dosage: Typically 10^9 Colony Forming Units (CFU) per day (1 billion CFU/day).
• Timing: Initiate early, alongside first enteral feeds, and continue daily until 34–36 weeks Post-Menstrual Age (PMA) or discharge.
• Composition: Multistrain combinations are widely considered more effective than single-strain regimens.

5. Safety, Quality Control, and Adverse Events

• Product Quality: Probiotics are widely sold as unregulated dietary supplements. Commercial preparations vary in purity and composition. Clinical protocols must mandate pharmaceutical-grade, third-party tested, or strictly validated preparations.
• Probiotic Sepsis (Bacteremia/Fungemia): Rare but confirmed cases of bloodstream translocation exist. This risk underscores the need for strict quality surveillance.
• Absolute Contraindications:
  • Known structural intestinal anomalies (e.g., gastroschisis, omphalocele).
  • Short Bowel Syndrome (risk of D-lactic acidosis).
  • Primary or severe secondary immunodeficiency disorders.
• Relative Contraindications/Precautions: Extreme prematurity (<750g or <26 weeks) or acute hemodynamic instability/active phase of NEC (hold doses during acute clinical deterioration).

6. Guidelines and Expert Disagreements

Professional societies remain divided regarding routine, universal administration of probiotics:

flowchart TD
    Start[Probiotics for Preterm Infants <1500g] --> Support[Support Routine Prophylactic Use]
    Start --> Caution[Caution / Do Not Support Routine Universal Use]

    Support --> ESPGHAN[ESPGHAN Position]
    ESPGHAN --> E1[Conditional support for specific, validated strains]
    ESPGHAN --> E2[Criticizes broad FDA restrictions as too restrictive]

    Caution --> AAP[AAP Position]
    AAP --> A1[Avoid routine use due to lack of FDA-regulated, pharma-grade options]
    AAP --> A2[Cites safety risks and high strain heterogeneity]

• ESPGHAN: Offers a conditional recommendation supporting specific strains (such as L. rhamnosus GG or a combination of B. infantis, B. lactis, and S. thermophilus). They advocate for a nuanced approach utilizing selected, verified strains rather than blanket restrictions.
• AAP: Concludes that current evidence does not support routine universal administration, citing a lack of regulated pharmaceutical-grade products, high strain heterogeneity, and potential safety concerns in the most fragile infants.

7. Evidence in Term Neonates

• There are currently no medical consensus guidelines supporting or recommending prophylactic probiotics in healthy, full-term newborns. A single large trial showed that a specific synbiotic preparation reduced sepsis in late-preterm and term low-birth-weight infants, but these findings cannot be generalized to standard healthy term infants.

8. Summary Clinical Pathway

flowchart TD
    Infant[Newborn Infant Evaluated in Unit] --> Criteria{Gestational Age <32 Weeks<br>OR Birth Weight <1500g?}
    
    Criteria -- No --> Term[Routine prophylaxis NOT recommended for healthy term infants]
    Criteria -- Yes --> Screen{Screen for Absolute Contraindications:<br>1. Intestinal anomalies?<br>2. Short bowel syndrome?<br>3. Severe immunodeficiency?}

    Screen -- Yes --> Hold[ABSOLUTE CONTRAINDICATION:<br>Do not administer probiotics]
    Screen -- No --> Assess{Assess Cautions & Relatives:<br>1. Extreme prematurity <750g / <26w?<br>2. Hemodynamic instability?}

    Assess -- Yes --> RiskBenefit[Perform Case-by-Case Risk/Benefit Review]
    RiskBenefit -- Decline --> Hold
    RiskBenefit -- Proceed with caution --> Protocol

    Assess -- No --> Protocol[Initiate Standard Clinical Protocol]

    subgraph Standard Treatment Protocol
        Protocol --> Dose[Dose: 10^9 CFU/day of validated multistrain product]
        Dose --> Start[Initiate early alongside first enteral feeds]
        Start --> Route[Adjunct to maternal breast milk or donor human milk]
        Route --> Maintain[Administer daily until 34-36 weeks PMA or discharge]
    end

    style Hold fill:#ffebee,stroke:#c62828,stroke-width:2px
    style Protocol fill:#e8f5e9,stroke:#2e7d32,stroke-width:2px